<DOC>
	<DOCNO>NCT00431106</DOCNO>
	<brief_summary>The combination vinorelbine gemcitabine seem important part chemotherapy regimen use metastatic breast cancer patient follow treatment failure combination taxane anthracycline . Capecitabine rescue monotherapy metastatic breast cancer patient follow treatment failure combination taxane anthracycline , also seem important part chemotherapy regimen use metastatic breast cancer patient . Whether combination vinorelbine gemcitabine capecitabine administration preferable yet know , especially patient metastatic disease .</brief_summary>
	<brief_title>Vinorelbine Gemcitabine Versus Capecitabine Pretreated Metastatic Breast Cancer</brief_title>
	<detailed_description>This trial compare efficacy combination treatment Vinorelbine Gemcitabine versus Capecitabine monotherapy metastatic breast cancer patient follow treatment failure combination taxane anthracycline .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Age 1975 year . Performance status World Health Organization ( WHO ) 02 . Histologically confirm breast adenocarcinoma . Clinical radiological evidence metastatic disease progress combination treatment taxane anthracycline ( Taxotere + Mitoxantrone Taxotere + Farmorubicine ) . Measurable disease . No metastatic central nervous system ( CNS ) disease . Less 25 % myeloproductive bone marrow irradiate . Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , hemoglobin &gt; 9 gr/mm^3 ) . Adequate liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2 mg/dl ) . Informed consent . Pregnancy nursing . Positive pregnancy test . Psychiatric illness social situation would preclude study compliance . Other concurrent uncontrolled illness . Other invasive malignancy within past 5 year except nonmelanoma skin cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Capecitabine</keyword>
</DOC>